

OSCIENT PHARMACEUTICALS CORP
Form 3
January 15, 2009

FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name and Ticker or Trading Symbol	
Â GLG Partners LP		(Month/Day/Year)	OSCIENT PHARMACEUTICALS CORP [OSCI]	
(Last)	(First)	(Middle)	11/25/2008	
1 CURZON STREET,Â		4. Relationship of Reporting Person(s) to Issuer		5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)		(Check all applicable)		6. Individual or Joint/Group Filing(Check Applicable Line)
LONDON,Â X0Â W1J 5HB		___ Director ___X_ 10% Owner		___ Form filed by One Reporting Person
(City)	(State)	(Zip)	___ Officer ___ Other (specify below)	
				__X_ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common stock, par value \$0.10 (the "Common Stock")	859,539	I <u>(1)</u> <u>(2)</u>	See Footnotes <u>(1)</u> <u>(2)</u>

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
		Title			

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 3

	Date Exercisable	Expiration Date		Amount or Number of Shares		or Indirect (1) (Instr. 5)	
12.50% Convertible Guaranteed Senior Notes	11/25/2008	01/15/2011	Common Stock	3,272,727	\$ 1.1	I (1) (2)	See Footnotes (1) (2)

Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
GLG Partners LP 1 CURZON STREET LONDON, X0 W1J 5HB	Â	Â X	Â	Â
GLG Partners LTD C/O GLG PARTNERS LP 1 CURZON STREET LONDON, X0 W1J 5HB	Â	Â X	Â	Â
GLG Partners, Inc. 390 PARK AVENUE 20TH FLOOR NEW YORK, NY 10022	Â	Â X	Â	Â
GLG Market Neutral Fund C/O GLG PARTNERS LP 1 CURZON STREET LONDON, X0 W1J 5HB	Â	Â X	Â	Â

Signatures

GLG Partners LP, By: GLG Partners Limited as its General Partner, By: /s/ Victoria Parry, Senior Legal Counsel of GLG Partners LP 01/15/2009

**Signature of Reporting Person Date

GLG Partners LP, By: GLG Partners Limited as its General Partner, By: /s/ Emmanuel Roman, Managing Director 01/15/2009

**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) GLG Partners LP, an English limited partnership, acts as the investment manager for GLG Market Neutral Fund, which owns 859,539 shares of Common Stock and \$3,600,000 aggregate principal amount of 12.50% Convertible Guaranteed Senior Notes due 2011, convertible into 3,272,727 shares of Common Stock.

(2) GLG Partners LP, an English limited partnership, acts as the investment manager of GLG Market Neutral Fund and may be deemed, as of the date hereof, to be the beneficial owner of the Issuer's securities or derivative securities held by GLG Market Neutral Fund. GLG Partners Limited, an English limited company, is the general partner of GLG Partners LP. GLG Partners, Inc. indirectly wholly owns GLG Partners Limited. GLG Partners LP, GLG Partners Limited and GLG Partners, Inc. do not hold directly any of the Issuer's securities or derivative securities with respect thereto, and disclaim any beneficial ownership of any of the Issuer's securities reported or excluded herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended, except for their pecuniary interest therein.

Edgar Filing: OSCIENT PHARMACEUTICALS CORP - Form 3

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.
Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.